JenaValve Technology, Inc.
Overview
JenaValve Technology, Inc. develops the Trilogy Transcatheter Heart Valve System, which is indicated for the treatment of symptomatic, severe native tricuspid aortic valve regurgitation in high-risk patients.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to JenaValve Technology, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.